ELISA 2.xlsx

Hepatocellular carcinoma (HCC) is the most common and aggressive type of liver cancer. Most chemotherapeutic medications nowadays imply oxidative stress leading to toxicity, which raises the necessity to find agents with better safety profiles against normal cells in addition to their anticancer activity. Sitagliptin has been shown to possess antioxidant as well as apoptotic properties by the specific suppression of dipeptidyl-peptidase 4, a glycoprotein produced in many tissues that have been thought to promote tumorigenesis and metastasis.肝细胞癌（HCC）是最常见且侵袭性最强的肝癌类型。当前多数化疗药物会诱发氧化应激进而引发毒性反应，这使得亟需开发兼具抗癌活性与更佳正常细胞安全性的抗肿瘤制剂。已有研究表明，西格列汀（Sitagliptin）可通过特异性抑制二肽基肽酶4（dipeptidyl-peptidase 4）——一种在多种组织中表达、被认为可促进肿瘤发生与转移的糖蛋白——发挥抗氧化及诱导细胞凋亡的作用。